Pernix Therapeutics Announces Omeclamox-Pak Now Available In Pharmacies Nationwide
Pernix Therapeutics (NYSE: PTX) today announced that Omeclamox-Pak® is now available to patients for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients. Omeclamox-Pak is a ten-day, triple combination oral therapy comprised of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg).
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.